CAJ | 학술논문

非瓣膜性心房颤动(房颤)相关性脑卒中的临床后果严重，是房颤致残、致死的最主要原因。口服华法林是预防房颤患者发生脑卒中事件的有效措施，但华法林的抗凝治疗窗窄，显效慢，疗效易受食物和药物的影响，故需反复检测凝血功能并根据国际标准化比值调整使用剂量，从而降低了患者的用药依从性。以凝血酶抑制剂及Ⅹa因子抑制剂为代表的新型口服抗凝剂较华法林能显著降低房颤相关性脑卒中的发病率和出血风险，有望成为房颤患者抗凝治疗的新选择。
비판막성심방전동(방전)상관성뇌졸중적림상후과엄중，시방전치잔、치사적최주요원인。구복화법림시예방방전환자발생뇌졸중사건적유효조시，단화법림적항응치료창착，현효만，료효역수식물화약물적영향，고수반복검측응혈공능병근거국제표준화비치조정사용제량，종이강저료환자적용약의종성。이응혈매억제제급Ⅹa인자억제제위대표적신형구복항응제교화법림능현저강저방전상관성뇌졸중적발병솔화출혈풍험，유망성위방전환자항응치료적신선택。
ABSTRACTNon-valvular atrial fibrillation related stroke causes severe clinical consequences,it is the main cause of disability and death of atrial ifbrillation. It is effective to prevent the occurrence of stroke in patients because of atrial ifbrillation with oral warfarin. But anticoagulant therapy with warfarin was associated with narrow therapeutic window and slow therapeutic effect. In addition ,the therapeutic effect was easily affected by foods and drugs. So repeated blood tests were performed which may reduce the medication compliance. The new oral anticoagulants, thrombin inhibitors and factor Xa inhibitors, can significantly reduce incidence of atrial fibrillation related stroke and risk of bleeding, and which may be expected to replace warfarin and will become a new choice for anticoagulation in patients for atrial ifbrillation in the future.